BLEEDING RISK IN SUBJECTS WITH SEVERE HEMOPHILIA ON VERY LOW DOSE AHF PROPHYLAXIS- AN OBSERVATIONAL STUDY

Abstract

Background: In order to strike a balance between cost-effectiveness and bleeding prevention, very low dose prophylaxis
of AHF (antihemophilic fever) in individuals with hemophilia uses lower and more frequent doses. In addition to cost-
effectiveness, a customized strategy, preventing overtreatment, and enhancing QoL (quality of life) in hemophilic people,
close monitoring of these subjects guarantees sufficient protection.
Aim: The purpose of this study was to evaluate the risk of bleeding in individuals with severe hemophilia who are
receiving very low doses of AHF prophylaxis. The study evaluated hemophilics' yearly AHF usage as well. The SF (social
functioning) 36 questionnaire was used in the study to measure the patients' quality of life. FISH (Functional
Independence Score in Hemophilia) was used to measure functional disability and to gauge the subjects' adherence to the
preventive regimen.
Methods: The current study evaluated individuals who had been diagnosed with hemophilia, reported to the Institute
within the specified study period, and were scheduled for surgical treatment. Participants in the study had to be at least
13 years old. The SF-36, FISH scores, annual AHF use, and bleeding risk were evaluated in each participant.
Results: FISH scores, SF-36 scores, the amount of AHF ingested, and ABR (annual bleeding rate) all showed statistically
significant differences between the two research groups with p<0.05.
Conclusion: The current investigation comes to the conclusion that very low-dose prophylaxis considerably reduces the
abnormal bleeding rate in hemophiliac patients. Significant gains in SF-36 scores are observed with AHF, while functional
independence deteriorates in those who are not on AHF. Additionally, AHF is more effective and preferable than on-
demand medication for low-dose prophylaxis.